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Abstract
Background: Buffered intravenous fluid preparations contain substrates to maintain acid-base status. The objective
of this systematic review was to compare the effects of buffered and non-buffered fluids administered during the
perioperative period on clinical and biochemical outcomes.
Methods: We searched MEDLINE, EMBASE, CINAHL and the Cochrane Library until May 2017 and included all
randomised controlled trials that evaluated buffered versus non-buffered fluids, whether crystalloid or colloid,
administered to surgical patients. We assessed the selected studies for risk of bias and graded the level of
evidence in accordance with Cochrane recommendations.
Results: We identified 19 publications of 18 randomised controlled trials, totalling 1096 participants. Mean
difference (MD) in postoperative pH was 0.05 units lower immediately following surgery in the non-buffered
group (12 studies of 720 participants; 95% confidence interval (CI) 0.04 to 0.07; I2 = 61%). This difference did
not persist on postoperative day 1. Serum chloride concentration was higher in the non-buffered group at
the end of surgery (10 trials of 530 participants; MD 6.77 mmol/L, 95% CI 3.38 to 10.17). This effect persisted
until postoperative day 1 (5 trials of 258 participants; MD 8.48 mmol/L, 95% CI 1.08 to 15.88). Quality of this
evidence was moderate. We identified variable protocols for fluid administration and total volumes of fluid
administered to patients intraoperatively. Outcome data was variably reported at disparate time points and
with heterogeneous patient groups. Consequently, the effect size and overall confidence interval was reduced,
despite the relatively low inherent risk of bias. There was insufficient evidence on the effect of fluid composition on
mortality and organ dysfunction. Confidence intervals of this outcome were wide and the quality of evidence was low
(3 trials of 276 participants for mortality; odds ratio (OR) 1.85, 95% CI 0.37 to 9.33; I2 = 0%).
Conclusions: Small effect sizes for biochemical outcomes and lack of correlated clinical follow-up data mean that
robust conclusions on major morbidity and mortality associated with buffered versus non-buffered perioperative fluid
choices are still lacking. Buffered fluid may have biochemical benefits, including a significant reduction in postoperative
hyperchloraemia and metabolic acidosis.
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Background
Major surgery presents an important threat to internal
homeostasis of fluid and electrolytes, partly due to the
volume depleting effects of haemorrhage, evaporative
loss and pre-operative dehydration, or by excessive fluid
administration causing oedema and organ dysfunction.
Intravenous fluid solutions used for resuscitation and
maintenance purposes should support the circulation
adequately to replace missing plasma, whilst avoiding
metabolic disturbance or other adverse effects. Modern
perioperative fluid management is based on the principle
that, as an intervention with risks and benefits, fluids
should only be provided to affect a meaningful clinical
variable. This principle influences decisions made for
monitoring requirements, timing of administration, vol-
ume dosing of fluids and the type of fluids provided to
patients.
Intravenous fluids, whether crystalloid or colloid, can
be categorised as buffered or non-buffered. Hartmann’s
fluid formulation more closely matches the constituents
of human plasma than 0.9% saline, containing a physio-
logical buffer that helps to maintain acid-base balance.
The composition of Hartmann’s fluid also includes add-
itional electrolytes found in plasma, including potassium,
magnesium and calcium. Provision of buffered crystal-
loid fluids may have benefits over 0.9% saline, in which
the electrolyte composition is significantly different to
the plasma that it is intended to replace.
The primary objective of this systematic review is to
investigate the clinical effects of perioperative adminis-
tration of buffered fluids, such as Hartmann’s solution,
when compared with non-buffered fluids administered
during all types of surgery.
Methods
This paper is an abridged version of a previously pub-
lished Cochrane systematic review (Bampoe et al. 2017).
We prepared this manuscript according to guidelines
published by Cochrane (Higgins and Green 2011) and
the PRISMA statement for systematic reviews and
meta-analysis (Moher et al. 2009). The full systematic re-
view protocol is available in the original Cochrane re-
view (Bampoe et al. 2017).
Search strategy
We searched publications in the Cochrane Central
Register of Controlled Trials (CENTRAL; 2016), MED-
LINE (1966 to May 2017), Embase (1980 to May 2017)
and the Cumulative Index to Nursing and Allied Health
Literature (CINAHL; 1982 to May 2017). No language
restrictions were applied to the search criteria. Relevant
conference abstract proceedings were also searched. For-
ward and backward citation tracking of all identified
studies was performed. The full search strategy used can
be found in the review protocol (Bampoe et al. 2017)
and in Additional file 1.
Inclusion and exclusion criteria
We included randomised controlled trials (RCTs) in
which patients received intravenous fluids with and
without a buffer (bicarbonate or bicarbonate precursor
buffer, such as maleate, gluconate, lactate, or acetate) for
the purpose of plasma volume expansion or mainten-
ance during the perioperative period. To minimise con-
founding factors, we considered only RCTs in which the
sole difference between experimental and control arms
involved the presence or absence of an electrolyte buffer
in the fluid. We excluded studies that compared crystal-
loids with colloids and those that compared fluids with
different colloid components. However, we included tri-
als with three or more arms that satisfied the other in-
clusion criteria. The perioperative period was defined as
extending from 2 h before the start of surgery up to 6 h
after surgery or until arrival to a post-anaesthetic care
unit. We included only studies that used isotonic fluids
(osmolarity 250 to 350 mmol/L) and a broadly physio-
logical concentration of sodium (120 to 160 mmol/L).
Data collection and analysis
Five review authors (TG, EB, AR, SB and PO) independ-
ently screened titles and abstracts of search results to re-
move irrelevant studies. Two review authors (SB and
PO) then reviewed full texts of potentially relevant titles
and identified studies that matched inclusion criteria.
Data on study characteristics and outcomes were inde-
pendently extracted from eligible studies by two authors
(SB and PO) with disagreements resolved by consensus
or by consultation with a third review author (EB). We
contacted the authors of included trials to request re-
quired data missing from published manuscripts.
Primary outcomes
1. Mortality (all time frames reported)
Secondary outcomes
1. Clinically significant organ system dysfunction
(including renal, pulmonary, hepatic,
gastrointestinal, coagulation and central nervous
system)
2. Surrogate measures of organ system dysfunction
including urine output, serum creatinine, partial
pressure of arterial carbon dioxide (PaCO2), nausea,
and vomiting
3. Biochemical or electrolyte disturbances including
pH, base excess, and serum bicarbonate, sodium,
potassium, calcium and chloride
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4. Serum measures of coagulation such as prothrombin
time, activated partial thromboplastin time, von
Willebrand factor, antithrombin 3 activity, fibrinogen
and thromboelastography
5. Blood loss or transfusion requirement
6. Postoperative hospital length of stay
7. Functional health status and quality of life measures
8. Cost
Assessment of risk of bias
We used the Cochrane risk of bias tool to assess the
quality of study design and extent of potential bias and
considered the following domains: sequence generation,
allocation concealment, blinding of participants, personnel
and outcome assessors, incomplete data and selective out-
come reporting (Higgins and Green 2011).
Statistical analysis
Data were analysed using Review Manager, version 5.3
(The Nordic Cochrane Centre 2012). For continuous
measures (e.g. urine output, serum electrolytes, post-op-
erative pH) we calculated mean differences (MD) with
95% confidence intervals (CIs) using an inverse variance
method. For dichotomous outcomes (e.g. mortality,
organ system failure), we calculated odds ratios (OR)
with 95% CI, using the Mantel-Haenszel method for
common outcomes (> 5%) and Peto OR for rare out-
comes (< 5%). When studies included more than two
groups, we merged data into groups when the interven-
tion was equivalent. Some studies included groups of
participants who did not receive the interventions of
interest, and we excluded these groups from analyses.
We conducted meta-analysis when it was reasonable
to assume that studies were estimating the same under-
lying treatment effect. We quantified the degree of het-
erogeneity in trial results using the I2 statistic (Higgins
and Green 2011). We assumed significant heterogeneity
when I2 was ≥ 40%. When heterogeneity was significant,
we used random-effects models. When I2 was < 40%, we
used a fixed effect model for analysis.
We planned to perform subgroup analysis to explore
sources of heterogeneity between studies. This was not
possible because we found insufficient studies reporting
our anticipated primary outcome of mortality. We per-
formed sensitivity analysis for the primary outcome to
explore the robustness of results based upon variation in
study quality and risk of bias assessment.
We judged the quality of evidence using GRADE
(GRADE Working Group, McMaster University 2015;
Guyatt et al. 2011). We based our assessment of the
quality of evidence on assessments of imprecision, in-
consistency, risk of bias, and indirectness for all studies
reporting specific outcome measures. We considered the
starting point to be “high quality” because of the
randomised design of all included studies. We down-
graded quality by one or two levels on the basis of as-
sessment of GRADE criteria and assessment of the
methodological quality and design of included studies.
Results
Study selection and characteristics
We identified 3979 unique citations from database
searches, manual searches and citation reviews. After
screening by title and abstract we then retrieved 41
full-text manuscripts for further analysis. Following the
review, 19 publications of 18 RCTs met the inclusion cri-
teria for study design, participants and interventions.
These 18 RCTs were incorporated into the quantitative
and qualitative analysis stage. Five trials were rejected
because of subsequent retractions of the paper, five trials
did not incorporate buffered fluid strategies, five trials
were of non-surgical patients, two were in vitro studies
and one trial was only available in abstract form. The
PRISMA flow chart is provided in Fig. 1.
The eighteen RCTs included a total of 1096 partici-
pants, of whom 563 received buffered fluids and 533 re-
ceived non-buffered fluids. Two papers reported one
trial, but different outcomes were described in the two
separate papers, showing no overlap, so these publica-
tions were considered separately (Martin et al. 2002;
Moretti et al. 2003). Five studies included patients with
renal transplants (Hadimioglu et al. 2008; Khajavi et al.
2008; Kim et al. 2013; Nuraei et al. 2010; O’Malley et al.
2005). As this population was different from the popula-
tion undergoing other perioperative procedures, we per-
formed sensitivity analysis, when possible, for renal
outcomes such as intraoperative urine output.
Most studies were small, single-site investigations.
Only two trials had a sample size of over 100 patients
across both intervention and control groups. Alongside
the five studies of renal transplant surgery, major elect-
ive surgery constituted the majority of procedures. This
included major orthopaedic, vascular (open aortic
aneurysm repair), gastrointestinal, hepatobiliary, gynae-
cological and urological surgery. One study of patients
undergoing coronary artery bypass grafting was included
and two studies included patients with minor surgical
procedures, which did not involve an invasion of body
cavities. No studies of patients undergoing emergency
surgery were identified.
The exact fluid type used and protocol for fluid
delivery to participants varied between studies. Of 18
included trials, 13 used crystalloids in both their experi-
mental and control arms. Of these studies, nine com-
pared lactated Ringer’s solution with 0.9% saline and
four compared Plasmalyte 148 with 0.9% saline. The
remaining six publications of five trials used colloid solu-
tions in their experimental and control arms, comparing
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a buffered hydroxyethyl starch (HES) solution versus a
non-buffered HES solution. High molecular weight
(MW) HES was used in four RCTs (Martin et al. 2002;
Moretti et al. 2003; Gan et al. 1999; Wilkes et al. 2001),
and two used low MW HES (Kulla et al. 2008; Base et
al. 2011).
Exclusive use of only buffered and non-buffered fluids
in each group was only maintained in seven of the 18 tri-
als. All other studies reported overlap, with the adminis-
tration of a combination of buffered and non-buffered
fluids in the control arm of the study. Hence, most studies
actually compared a partially buffered fluid regimen versus
a totally buffered fluid regimen.
Risk of bias in included studies
All trials were randomised, with a total of 16 studies that
referred to blinding or double-blinding in their design
and had a low risk of performance and detection bias.
Fifteen trials provided details about allocation sequence
generation and twelve studies described allocation con-
cealment; these studies were considered to be at low risk
of selection bias. We judged only one trial to be at high
risk of attrition bias because a high proportion of partici-
pants dropped out of the trial owing to the administra-
tion of non-protocol intravenous fluids; the remainder
were a low or unclear risk of bias. We did not detect
reporting bias and therefore categorised all studies as
low risk.
Pharmaceutical companies that manufactured an inter-
vention of interest funded five of the included studies
(Martin et al. 2002; Moretti et al. 2003; Gan et al. 1999;
Wilkes et al. 2001; Base et al. 2011). Although each study
clearly disclosed these funding sources, we considered
these studies to be at unclear risk of bias. Two other stud-
ies did not report sufficient detail about outcomes of inter-
est, and we therefore considered them to be at unclear
risk of bias (Kulla et al. 2008; Heidari et al. 2011).
Generally, participant numbers in these trials were
low, with four trials enrolling fewer than 20 participants
in each arm. Consequently, many outcome measures are
reported in small group sizes, reducing overall confi-
dence in effect size, despite relatively low inherent bias
in the included studies. Risk of bias of included studies
is summarised in Fig. 2.
Primary outcome
Three clinical trials with a total of 267 participants re-
ported mortality (Gan et al. 1999; Base et al. 2011; Wa-
ters et al. 2001). Mortality was low in both groups: 2.9%
(4/136) in the buffered group and 1.5% (2/131) in the
non-buffered group. The limited data suggests no signifi-
cant mortality differences between groups (OR 1.85, 95%
CI 0.37 to 9.33; I2 = 0%). The quality of evidence was
downgraded from high to low owing to the imprecision
Fig. 1 Prisma study flow diagram
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of trial results due to small sample sizes, wide confi-
dence intervals and methodological variability between
studies. Studies reporting mortality presented few
events, and all three studies were considered to be at un-
clear risk of bias for this outcome assessment. Overall
confidence in the effect estimate is low. A forest plot for
the primary outcome is provided in Fig. 3.
Secondary outcomes
Clinically significant organ system dysfunction
We found low-quality and insufficient evidence to sup-
port any effects of fluid therapies on postoperative organ
failure. Renal failure leading to the requirement for renal
replacement therapy was reported in four trials (Hadi-
mioglu et al. 2008; Kim et al. 2013; O’Malley et al. 2005;
Waters et al. 2001), although three of these studies
included participants with the confounding effect of
pre-existing organ insufficiency (i.e. participants
undergoing renal transplant for renal failure) (Hadi-
mioglu et al. 2008; Kim et al. 2013; O’Malley et al.
2005). There was no evidence to support a lower risk
of renal failure with buffered fluids (OR 0.82, 95% CI
0.34 to 1.98; I2 = 0%). A single study reported respira-
tory failure, enrolling 81 participants with a 9.3% (4/
43) incidence of post-operative respiratory failure in
the buffered group and 2.6% (1/38) in the non-buff-
ered group. No reports of cardiac, hepatic, gastro-
intestinal or neurological failure were recorded as
outcomes measures.
Surrogate measures of organ system dysfunction
Urine output Eight trials with a total of 459 participants
reported urine output during the intraoperative period
and on the first postoperative day (Kim et al. 2013;
O’Malley et al. 2005; Kulla et al. 2008; Gan et al. 1999;
Wilkes et al. 2001; Waters et al. 2001; Scheingraber et al.
1999; Takil et al. 2002). Mean urine output reported in-
traoperatively was 872 ml for the buffered fluid group
and 799 ml for the non-buffered fluid group. The mean
difference was 6.1 ml higher in the buffered group (95%
CI − 128.41 to 140.61; I2 = 49%). Sensitivity analysis was
performed to exclude the four studies that included
renal transplant patients (Khajavi et al. 2008; Kim et al.
2013; Nuraei et al. 2010; O’Malley et al. 2005), which
confirmed no important differences between groups for
intraoperative urine output. One of the two trials report-
ing urine output on the first post-operative day enrolled
renal transplant patients and reported disproportionately
large volumes of urine output (Hadimioglu et al. 2008).
Due to this clinical heterogeneity, no further meta-ana-
lysis was conducted on this outcome measure.
Post-operative serum creatinine Two trials of 113
participants reported relative post-operative serum
creatinine change at two time points: immediately
post-operatively and on post-operative day one
(Wilkes et al. 2001; Waters et al. 2001). No groups
showed any significant differences. Mean difference
was 6.96 μmol/L lower in the buffered group (95% CI
Fig. 2 Risk of bias graph. Review authors’ judgments about each risk of bias item presented as percentages across all included studies
Fig. 3 Comparison: buffered perioperative fluids vs non-buffered fluids. Outcome: mortality
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− 27.42 to 13.50; I2 = 89%) in the immediate
post-operative measurement and 4.94 μmol/L lower in
the non-buffered group (95% CI -5.91 to 15.78; I2 =
12%) on post-operative day one.
Absolute creatinine was reported at time points from
post-operative day one to day seven. Three trials with a
total of 235 participants reported absolute immediate
post-operative creatinine values (Nuraei et al. 2010;
Kulla et al. 2008; Waters et al. 2001). The mean creatin-
ine in two studies of non-renal transplant participants
was 76.72 μmol/L in the buffered fluid group and
79.53 μmol/L in the non-buffered group. One study in-
cluded renal transplant patients, reporting a significantly
different mean creatinine as 530 μmol/L in the buffered
fluid group and 460 μmol/L in the non-buffered group
(MD 70 μmol/L higher; 95% CI 14.31 to 125.69). Data
show no important overall differences between groups.
Overall, the MD was − 1.31 μmol/L lower in the
non-buffered group (95% CI − 9.30 to 6.68; I2 = 71%).
Three trials with a total of 211 participants reported
postoperative day one creatinine (Hadimioglu et al.
2008; Kim et al. 2013; Kulla et al. 2008). Two studies
enrolled renal transplant patients (Hadimioglu et al.
2008; Kim et al. 2013). Overall data show a mean dif-
ference 6.26 μmol/L lower in the buffered group (95%
CI − 21.17 to 8.64; I2 = 0%); there were no significant
differences between subgroups of renal transplant and
non-transplant patients.
Four trials of participants undergoing renal transplants
reported post-operative day 3 and day 7 creatinine
(Hadimioglu et al. 2008; Khajavi et al. 2008; Nuraei et al.
2010; O’Malley et al. 2005). There was no significant dif-
ference in creatinine between the buffered group and
non-buffered groups at either time point.
In summary, only one trial showed a significant differ-
ence in creatinine outcomes (Nuraei et al. 2010), with a
higher immediately post-operative creatinine measured
in the buffered fluid group. There were no other statisti-
cally (or clinically) significant differences.
Partial pressure of arterial carbon dioxide (PaCO2)
Seven trials with a total of 446 participants reported
postoperative PaCO2 at two time points (Hadimioglu et
al. 2008; Kim et al. 2013; Nuraei et al. 2010; Kulla et al.
2008; Wilkes et al. 2001; Song et al. 2015; Takil et al.
2002. Results show a statistically (but unlikely clinically)
significant higher mean PaCO2 of 35.0 mmHg in the
buffered fluid group than in the non-buffered fluid
group (MD 1.05 mmHg, 95% CI 0.15 to 1.94; I2 = 0%).
Two trials with a total of 91 participants reported post-
operative day one PaCO2 of 41 mmHg in the buffered
fluid group and 37.7 mmHg in the non-buffered fluid
group (Kulla et al. 2008; Takil et al. 2002). PaCO2 was
significantly higher in the buffered group (MD
3.3 mmHg, 95% CI 2.03 to 4.64; I2 = 0%).
Postoperative vomiting Three trials reported 21/84
(25%) episodes of postoperative vomiting in the buffered
fluid group and 28/84 (33%) episodes of postoperative
vomiting in the non-buffered fluid group (Moretti et al.
2003; Wilkes et al. 2001; Heidari et al. 2011). There was
no significant difference in post-operative vomiting be-
tween groups (OR 0.66, 95% CI 0.34 to 1.30; I2 = 20%).
Biochemical or electrolyte disturbance
pH Twelve studies with a total of 720 participants
reported postoperative pH (Hadimioglu et al. 2008;
Khajavi et al. 2008; Kim et al. 2013; Nuraei et al. 2010;
O’Malley et al. 2005; Kulla et al. 2008; Wilkes et al.
2001; Waters et al. 2001; Scheingraber et al. 1999; Song
et al. 2015; Takil et al. 2002). Reporting was heteroge-
neous with different time intervals. Mean postoperative
pH was 7.38 in the buffered fluid group and 7.32 in the
non-buffered fluid group. There was a significant differ-
ence, with postoperative pH 0.05 units lower (95% CI −
0.04 to − 0.07; I2 = 61%) in the non-buffered group. A
forest plot of this outcome is found in Fig. 4.
Base excess Investigators reported this outcome at vari-
ous time intervals. Nine studies with a total of 459 par-
ticipants reported postoperative base excess. Mean base
excess was negative for both fluid groups: − 1.65 mmol/
L in the buffered fluid group and − 5.02 mmol/L in the
non-buffered fluid group (Hadimioglu et al. 2008; Kim
et al. 2013; O’Malley et al. 2005; Wilkes et al. 2001; Wa-
ters et al. 2001; Scheingraber et al. 1999; Song et al.
2015; Takil et al. 2002; McFarlane and Lee 1994). There
was a significant difference between groups, with post-
operative base excess 3.51 mmol/L lower in the
non-buffered fluid group than in the buffered fluid
group (95% CI 2.61 to 4.41). A forest plot of this out-
come is found in Fig. 5.
Serum bicarbonate Seven studies with a total of 478
participants reported postoperative serum bicarbonate.
Mean postoperative serum bicarbonates was 21.6 mmol/
L in the buffered fluid group and 18.6 mmol/L in the
non-buffered fluid group (Hadimioglu et al. 2008; Kim
et al. 2013; O’Malley et al. 2005; Waters et al. 2001;
Scheingraber et al. 1999; Song et al. 2015; Takil et al.
2002). There was a significant difference between
groups, with serum bicarbonate 3.14 mmol/L lower in
the non-buffered group (95% CI 2.30 to 3.98).
Serum sodium Eight trials with a total of 447 participants
reported a postoperative serum sodium concentration of
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137.3 mmol/L in the buffered fluid group and
139.4 mmol/L in the non-buffered fluid group (Khajavi et
al. 2008; Kim et al. 2013; Nuraei et al. 2010; Kulla et al.
2008; Wilkes et al. 2001; Waters et al. 2001; Song et al.
2015; Takil et al. 2002). There was a significant difference
between groups, with MD − 2.26 mmol/L higher in the
non-buffered group (95% CI - 2.84 to − 1.68; I2 = 56%;).
Two trials with a total of 91 participants reported postop-
erative day one serum sodium of 140.6 mmol/L in the
buffered fluid group and 141.8 mmol/L in the
non-buffered fluid group (Kulla et al. 2008; Takil et al.
2002). There were no significant differences between
groups, with serum sodium 1.2 mmol/L higher in the
non-buffered fluid group (95% CI -2.55 to 0.12; I2 = 0).
Serum potassium Seven trials with a total of 459 partic-
ipants reported postoperative serum potassium. Potas-
sium was 4.13 mmol/L in the buffered group and
4.22 mmol/L in the non-buffered group (Hadimioglu
et al. 2008; Khajavi et al. 2008; Nuraei et al. 2010;
Fig. 4 Comparison: buffered perioperative fluids vs non-buffered fluids. Outcome: postoperative pH
Fig. 5 Comparison: buffered perioperative fluids vs non-buffered fluids. Outcome: post-operative base excess
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O’Malley et al. 2005; Kulla et al. 2008; Wilkes et al.
2001; Song et al. 2015). There were no significant differ-
ences between groups, with MD − 0.04 mmol/L lower in
the buffered group (95% CI − 0.14 to 0.06; I2 = 65%).
Serum chloride Ten studies with a total of 530 partici-
pants reported postoperative serum chloride. Postopera-
tive chloride was 107.5 mmol/L in the buffered fluid
group and 114.3 mmol/L in the non-buffered fluid group
at this time point (Hadimioglu et al. 2008; O’Malley et
al. 2005; Kulla et al. 2008; Wilkes et al. 2001; Base et al.
2011; Waters et al. 2001; Scheingraber et al. 1999; Song
et al. 2015; Takil et al. 2002; McFarlane and Lee 1994).
Serum chloride was significantly higher in the
non-buffered fluid group (95% CI − 10.17 to − 3.38) with a
MD 6.77 mmol/L. Five studies, including 258 participants,
reported a mean serum chloride on the first postoperative
day. Serum chloride continued to be significantly elevated
into the first post-operative day with of 105.7 mmol/L in
the buffered fluid group and 114.4 mmol/L in the
non-buffered fluid group (Hadimioglu et al. 2008; Kim et
al. 2013; Kulla et al. 2008; Wilkes et al. 2001; Takil et al.
2002). Serum chloride was 8.48 mmol/L higher in the
non-buffered fluid group (95% CI − 15.88 to − 1.08).
Serum glucose Three trials reported postoperative
serum glucose of 6.0 mmol/ L for both buffered and
non-buffered groups. There was no difference between
groups (95% CI − 0.29 to 0.29; I2 = 0%) (Wilkes et al.
2001; Waters et al. 2001; Chin et al. 2006).
Serum lactate No difference between groups in terms
of serum lactate was identified in four trials, with a total
of 199 participants. Pooled data showed a mean serum
lactate of 2.27 mmol/L in the buffered fluid group and
1.62 mmol/L in the non-buffered fluid group (MD
0.52 mmol/L higher in the buffered group; 95% CI −
0.04 to 1.08).
Serum measures of coagulation
Limited data was found on clotting factor concentrations
and functional measures of coagulation in the included
studies. Two studies with a total of 181 participants
(Kulla et al. 2008; Gan et al. 1999) reported activated
partial thromboplastin time (APTT), Factor VIII and
von Willebrand factor (vWF). Only serum vWF concen-
tration was found to be significantly different between
groups, with a mean difference 31.4 IU/L lower in the
buffered fluid group than in the non-buffered fluid
group (95% CI − 47.7 to − 15.1; I2 = 0%). The clinical sig-
nificance of this finding is unclear. One trial reported
prothrombin time (PT) (Gan et al. 1999), which was not
significantly different between groups. Three trials re-
ported thromboelastographic (TEG) data (Martin et al.
2002; Gan et al. 1999; Song et al. 2015). Two studies re-
ported postoperative TEG data graphically (Martin et al.
2002; Gan et al. 1999). Therefore, we did not subject this
measure to meta-analysis.
Blood loss Eleven trials of 576 participants reported ab-
solute intraoperative blood loss in millilitres (Martin et
al. 2002; Khajavi et al. 2008; O’Malley et al. 2005; Kulla
et al. 2008; Gan et al. 1999; Wilkes et al. 2001; Schein-
graber et al. 1999; Song et al. 2015; Takil et al. 2002;
Walsh et al. 1983). Two studies reported estimated
blood loss in millilitres/kilograms and could not be in-
cluded in the analysis because they did not report pa-
tient weight (Base et al. 2011; McFarlane and Lee 1994).
Reflective of varied types of surgery conducted, ranging
from abdominal aortic aneurysm repair to day case sur-
gery, clinical heterogeneity between these trials was high.
Two trials reporting less than 400 ml of estimated blood
loss (O’Malley et al. 2005; Walsh et al. 1983) and two tri-
als reporting estimated blood loss of 2 L or more (Wa-
ters et al. 2001; Takil et al. 2002). These results made it
unlikely that any analysis would yield a clinically signifi-
cant result if the group was analysed as a whole.
We performed a subgroup analysis to attempt to re-
duce clinical heterogeneity by grouping trials with less
than 1000 ml of blood loss and those with blood loss of
1000 ml or more. Trials reporting blood loss less than
1000 ml (five studies with 202 participants) reported no
important differences between groups and showed mean
difference in intraoperative blood loss that was 5.90 ml
higher in the buffered group (95% CI − 45.18 to 56.99;
I2 = 0%) (Khajavi et al. 2008; O’Malley et al. 2005; Kulla
et al. 2008; Scheingraber et al. 1999; Walsh et al. 1983).
Trials reporting blood loss of 1000 ml or more (six studies
with 374 participants) also reported no important differ-
ences in blood loss between groups and showed mean dif-
ference in intraoperative blood loss that was 173 ml lower
in the buffered group (95% CI − 438.8 to 92.7; I2 = 13%)
(Martin et al. 2002; Gan et al. 1999; Wilkes et al. 2001;
Waters et al. 2001; Song et al. 2015; Takil et al. 2002).
Transfusion requirement Seven trials of 409 partici-
pants reported intraoperative red blood cells, platelet or
fresh frozen plasma transfusion (Martin et al. 2002;
O’Malley et al. 2005; Gan et al. 1999; Wilkes et al. 2001;
Scheingraber et al. 1999; Takil et al. 2002. There was no
significant difference in the quantity of any blood prod-
ucts transfused between individuals given buffered fluids
and those given non-buffered solutions.
Post-operative hospital length of stay
Five trials with a total of 348 participants reported hos-
pital length of stay (O’Malley et al. 2005; Gan et al. 1999;
Base et al. 2011; Waters et al. 2001; Takil et al. 2002).
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Established formulae were used to numerically convert
median (IQR) data to mean (± SD) (Hozo et al. 2005).
There were no significant differences between groups,
with MD in-hospital stay of 0.37 (95% CI − 0.72 to 1.47;
I2 = 16%; favouring the non-buffered group).
Other
None of the included trials addressed the outcomes of
cost or functional health status, cost or quality of life
measures.
Biochemical outcomes from all studies are summarised
in Tables 1 and 2. Extracted data from included studies
is contained in a table in Additional file 2: Table S1. A
summary of the primary and significant findings from a
meta-analysis is included in Additional file 3: Table S2.
Discussion
The effects of intravenous fluid on clinical outcomes is a
topic of major interest, which has been thoroughly ex-
plored in critical care patients but remains controversial in
the peri-operative setting. This systematic review provides
a comprehensive analysis of current data, demonstrating a
paucity of high-quality trials with relevant patient-centred
outcomes. It is surprising that the randomised controlled
trial data available for meta-analysis is so small, relative to
the millions of patients that receiving intravenous fluids
during surgery each year. Our data shows that for three
studies including 267 patients, the choice of perioperative
fluid, either buffered or unbuffered did not result in a sig-
nificant difference in mortality. The GRADE evidence for
this outcome was rated as low. The overall combined mor-
tality from these studies was low at 2%.
The analysis of secondary outcome measures from 18
different RCTs of 1096 participants suggests that intraven-
ous fluids containing a physiological buffer are a safe alter-
native to saline-based fluids for adult patients undergoing
surgery. We found limited evidence on the effects of fluid
therapies on postoperative organ dysfunction, particularly
on renal failure. For patients not undergoing renal trans-
plantation, there were no differences in terms of renal in-
sufficiency or surrogate markers of renal dysfunction
(urine output and serum creatinine). However, there were
differences in metabolic variables in post-operative pH,
chloride concentration, base-deficits and serum bicarbon-
ate, without significant changes in other electrolytes such
as serum potassium and sodium concentrations. High
serum chloride is a cause of metabolic acidosis and may
explain our findings of both lower pH and lower partial
pressure of arterial carbon dioxide (PaCO2) (secondary to
respiratory compensation for metabolic acidosis) when
non-buffered fluids were used. We rated GRADE evidence
for these secondary outcomes as low-moderate quality.
This review focused on the type of perioperative fluid
administration. Evidence from studies investigating the
Table 1 Summary of differences in renal function outcomes between non-buffered and buffered fluid groups
Outcomes Absolute effects No. of participants
(studies)
p
Outcome with non-buffered
fluid (mean)
Outcome with buffered fluid
(mean; mean difference with 95% CI)
Urine output—intraoperative 799 ml 872 ml
(MD 6.1 ml higher; 95% CI − 128.4 to 140.6)
459 (8 RCTs) 0.93
Creatine change—postoperative MD in creatinine was 7.0 μmol/L lower in the buffered fluids group;
95% CI − 27.4 to 13.5
113 (2 RCTs) 0.50
Creatine change—postoperative day 1 MD in creatinine was 4.9 μmol/L lower in the buffered fluids group;
95% CI − 5.9 to 15.8
113 (2 RCTs) 0.37
Creatinine—postoperative Non-transplant patients 127 (2 RCTs) 0.59
79.5 μmol/L 76.2 μmol/L
(MD 2.38 μmol/L lower; 95% CI − 10.98 to 6.23)
Renal transplant patients 110 (1 RCT) 0.01
460 μmol/L 530 μmol/L
(MD 70 μmol/L higher; 95% CI 14.31 to 125.69)
Creatinine—postoperative day 1 Non-transplant patients 61 (1 RCT) 0.44
80 μmol/L 86 μmol/L
(MD 6 μmol/L higher; 95% CI − 21.23 to 9.23)
Renal transplant patients 150 (2 RCTs) 0.74
353.5 μmol/L 336 μmol/L
(MD 12.26 μmol/L lower; 95% CI − 85.10 to 60.57)
Creatinine—postoperative day 3 Renal transplant patients 301 (4 RCTs) 0.98
168 μmol/L 173 μmol/L
(MD 0.47 μmol/L higher; 95% CI − 30.12 to 29.19)
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volume of fluid and haemodynamic monitoring suggest
that decisions regarding perioperative fluid strategy can
influence outcome after surgery. Hence, it is not just the
type of fluid that is important, but exactly how the fluid is
administered, in terms of volume and timing. Protocols
for fluid administration in the included studies in this re-
view were seldom available. Studies of goal-directed fluid
therapy offer supportive evidence for reduced morbidity
and length of hospital stay (Pearse et al. 2014), but poor
evidence for reductions in mortality (Calvo-Vecino et al.
2018). Excessive volumes of fluid administration have
been associated with harm, such as pulmonary complica-
tions and tissue oedema. However, the current trend for
conservative fluid administration, as advocated in many
perioperative enhanced recovery pathways, has also been
recently disputed a major trial measuring an increased
proportion of acute kidney injury in patients who received
a zero fluid balance regimen in the perioperative period
(Myles et al. 2018). In the face of conflicting evidence, get-
ting the fluid strategy right is not easy. However, it is be-
coming clear that an inflexible, “one size fits all” approach
when planning perioperative fluid management may not
be the best approach, and a strategy that has been indivi-
dualised to each patient may be more appropriate with
many variable factors taken into consideration. This is
reflected in fluid management consensus statements
such as the recent American Society of Enhanced Re-
covery and Perioperative Quality Initiative (POQI) joint
statement that advocates an individualised approach to
fluid management, taking into account patient-specific
variables (Thiele et al. 2016).
In addition to haemodynamic optimisation and total
volume dosing, fluid electrolyte composition is also import-
ant to consider. Perceived advantages of balanced crystalloid
solutions over non-buffered solutions are reflected in the
British Consensus Guidelines on Intravenous Fluid Therapy
for Adult Surgical Patients (GIFTASUP) (Powell-Tuck et al.
2011) that recommend the use of balanced solutions for
crystalloid fluid resuscitation or replacement.
Our findings are consistent with a recent systematic
review and meta-analysis, which included studies from
ICU patients and demonstrated no difference in the out-
comes of hospital mortality, the occurrence of acute kid-
ney injury or need for renal replacement therapy with
balanced intravenous fluid resuscitation (Neto et al.
2017). A large single centre, pragmatic, crossover trial
comparing lactated Ringer’s solution or Plasma-Lyte A
with saline in emergency admissions of non-critically ill
adults was published recently. This study, whilst not ex-
clusively conducted in peri-operative patients, included
about 20% of general surgical patients and concluded
that there was no significant between-group difference
Table 2 Summary of differences in serum biochemistry between non-buffered and buffered fluid groups
Outcomes Absolute effects No. of participants
(studies)
p
Outcome with non-buffered
fluid (mean)
Outcome with buffered fluid
(mean; mean difference with 95% CI)
PaCO2 35.0 mmHg 34.9 mmHg
(MD 1 mmHg higher; 95% CI 0.15 to 1.94)
446 (7 RCTs) 0.02
Postoperative pH 7.32 7.38
(MD 0.05 units higher; 95% CI 0.04 to 0.07)
720 (12 RCTs) < 0.0001
Base excess − 5.0 − 1.65
(MD 3.5 units higher; 95% CI 2.6 to 4.4)
459 (9 RCTs) < 0.0001
Serum bicarbonate 18.6 mmol/L 21.6 mmol/L
(MD 3.14 mmol/L; 95% CI 2.3 to 4.0)
478 (8 RCTs) < 0.0001
Serum sodium—postoperative 139.4 mmol/L 137.3 mmol/L
(MD 0.52 mmol/ L higher; 95% CI − 2.8 to − 1.7)
447 (8 RCTs) < 0.0001
Serum sodium—postoperative
day 1
141.8 mmol/L 140.6 mmol/L
(MD 0.52 mmol/ L higher; 95% CI − 2.8 to −1.7)
91 (2 RCTs) 0.07
Serum potassium 4.22 mmol/L 4.13 mmol/L
(MD 0.04 mmol/ L lower; 95% CI − 0.14 to 0.06)
459 (7 RCTs) 0.43
Serum chloride—postoperative 114.3 mmol/L 107.5 mmol/L
(MD 6.77 mmol/ L lower; 95% CI − 3.38 to −10.17)
530 (10 RCTs) 0.0001
Serum chloride—postoperative
day 1
114.4 mmol/L 105.7 mmol/L
(MD 8.48 mmol/ L lower; 95% CI − 15.88 to −1.08)
258 (5 RCTs) 0.02
Serum glucose 6.0 mmol/L 6.0 mmol/L
(MD no difference; 95% CI − 0.29 to 0.29)
145 (3 RCTs) 0.99
Serum lactate 1.6 mmol/L 2.3 mmol/L
(MD 0.52 mmol/ L higher; 95% CI − 0.04 to 1.1)
199 (4 RCTs) 0.067
Serum calcium 1.6 mmol/L 2.0 mmol/L 47 (1 RCT) 0.0001
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in mortality or hospital-free days at day 28. However, the
incidence of major adverse kidney events, within 30 days,
was lower with balanced fluids (4.7%), compared with
saline (5.6%) (Self et al. 2018). A similar trial design was
adopted by a multi-centre study of > 15,000 critically ill
patients comparing saline with buffered crystalloids (lac-
tated Ringer’s solution or Plasma-Lyte A) that reported a
reduction of 1.1% in the composite primary outcome of
major adverse kidney events within 30 days (Semler et
al. 2018). In both of these studies, the primary outcome
of major adverse kidney event within 30 days was de-
fined as a composite of death, new-renal replacement
therapy or persistent renal dysfunction (final serum cre-
atinine concentration of > 200% of the baseline). Whilst
these large pragmatic studies are highly informative, they
were open-label trials reporting a composite outcome,
which can be associated with potential caveats of mul-
tiple sources of bias and are not specific to surgical
patients.
A further, recent study was published subsequent to
the search strategy for this review and is therefore not
included in the meta-analysis. This double-blind rando-
mised trial of saline versus balanced crystalloid for
goal-directed perioperative fluid therapy in major ab-
dominal surgery patients was terminated for safety rea-
sons after recruiting 60 patients of a planned sample size
of 240 (Pfortmueller et al. 2018). Patients in the saline
group developed hyperchloraemic metabolic acidosis,
but also a dose-dependent increase in vasopressor re-
quirements, despite no difference in total in total peri-
operative fluid volumes. This study signals a serious
measure of harm, albeit in an underpowered study for-
mat, for perioperative saline administration.
Whilst we used an inclusive search strategy and eligi-
bility criteria to maximise identification of relevant stud-
ies, this meant that there was considerable clinical
heterogeneity in participant characteristics, types of sur-
gery and protocols for administering fluids in the trials.
Some RCTs involved minor surgery in otherwise healthy
patients (Chin et al. 2006), whilst others analysed out-
comes after very major surgery in high-risk patient
groups (Wilkes et al. 2001; Waters et al. 2001). This is
important because both the baseline values and toler-
ance of the magnitude of homeostatic derangement will
vary with patient organ function, meaning that a single
recommendation cannot be generalised to the whole
patient population. For example, an observation that
fluid choice influences renal failure in patients with
pre-existing severe renal dysfunction is unlikely to be
applicable to patients with normal glomerular filtra-
tion rates. Subgroup analysis and reporting of mul-
tiple secondary outcomes was conducted in order to
clarify the results from pooled data. Only trials in-
cluded adult perioperative patients were included,
hence conclusions cannot be directly drawn for
paediatric or medically unwell patients from this
meta-analysis. Whilst statistical heterogeneity for our
primary outcome of mortality was very low (I2 = 0),
many of our secondary outcomes displayed substan-
tially greater statistical heterogeneity.
Some trial data did not contribute to our analyses be-
cause they were reported in weight-based units rather
than in absolute amounts. We attempted to contact trial
authors to obtain individual participant data, but we
were not always successful in these attempts.
This review identified small numbers of patients and
low numbers of events across outcomes of interest, in-
cluding the primary outcome of mortality. Alongside this
several of the studies were poorly reported and at high
or unclear risk of bias. Where relevant, the consequent
downgrading of the quality of evidence reduces the con-
fidence in reported effects in pooled data.
Although there are a substantial number of studies in
this systematic review, no single, large pragmatic and ap-
propriately blinded randomised controlled trial was identi-
fied with sufficient power to detect important differences
in clinical outcomes arising from the choice of periopera-
tive fluid. In particular, acute kidney injury should be con-
sidered as an important and patient-relevant outcome
measure. The SOLAR fluid trial, a large study of saline
versus Ringer’s lactate that is assessing major postopera-
tive complications as its primary outcome measure, is cur-
rently ongoing and expected to be completed in 2022
(SOLAR trial 2017).
Buffered and non-buffered fluids have predictable ef-
fects on post-operative biochemical parameters in surgi-
cal patients, are appropriate for fluid replacement and
should be considered especially for patients with, or at
risk of, metabolic derangement. No complications or ad-
verse effects specific to buffered fluids were identified in
surgical patients with a range of co-morbidities and
organ dysfunction.
Additional studies are needed, including well designed
and adequately powered randomised controlled trials to
detect differences in clinical outcomes arising from the
physician’s choice of perioperative fluid. Such studies
should include meaningful patient-centred outcomes such
as mortality, quality of recovery, length of hospital stay,
and organ dysfunction (including acute kidney injury) and
quality of life measures such as postoperative pain.
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